Key result
This letter discusses the MAPLE-HCM trial, which compared aficamten to metoprolol for exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Why the study?
Does aficamten improve exercise capacity compared to metoprolol in patients with symptomatic obstructive HCM?
Does aficamten improve exercise capacity compared to metoprolol in patients with symptomatic obstructive HCM?
This letter discusses the implications of the MAPLE-HCM trial, raising considerations about whether aficamten should replace beta-blockers as the first-line therapy for symptomatic obstructive HCM.
To the Editor: The MAPLE-HCM (Metoprolol versus Aficamten in Patients with Left Ventricular Outflow Tract Obstruction on Exercise Capacity in HCM [Hypertrophic Cardiomyopathy]) trial, conducted by Garcia-Pavia et al. (Sept. 11 issue), 1 was a landmark trial involving patients with obstructive HCM. Beta-blockers have historically been the first-line medication for symptomatic obstructive HCM despite a paucity of evidence from randomized trials. 2 Favorable results from this trial raise questions about abandoning beta-blockers for aficamten as the initial treatment for patients with symptomatic obstructive HCM. The design of this trial and other practical considerations warrant attention before advocating this approach. With respect to . . .
No takes yet. Share an insight, caveat, or question.
A 2025 study conducted a letter in Symptomatic obstructive hypertrophic cardiomyopathy. Aficamten vs. Metoprolol was evaluated on Exercise capacity. This letter discusses the MAPLE-HCM trial, which compared aficamten to metoprolol for exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: